First Patient Enrolled in ProstACT TARGET Study
MELBOURNE, Australia, Sept. 27, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and GenesisCare, the largest provider of integrated cancer care in Australia, today announce that a first patient has been enrolled in the Phase II ProstACT TARGET study of Telix's prostate cancer antibody therapy candidate TLX591 (177Lu-DOTA-rosopatamab), in patients...
Mindray Showcases Hematology Innovations and Academic Achievements to the World at ISLH 2022
BOLOGNA, Italy, Sept. 26, 2022 /PRNewswire/ -- The International Symposium on Technological Innovations in Laboratory Hematology, (ISLH 2022), was held between September 8-10 in Bologna, Italy. This event saw Mindray (SZSE: 300760), a global leading developer and provider of medical devices and solutions, showcase their hematology innovations and academic achievements to medical experts from Europe and around the world. Held annually,...
AXA BetterMe Weekend comes back on 8 to 9 October
Free carnival at West Kowloon Cultural District to promote holistic wellness Covering the elements of physical & mental wellness, art and green lifestyle HONG KONG, Sept. 26, 2022 /PRNewswire/ -- To mark and celebrate the World Mental Health Day on 10 October, AXA Hong Kong and Macau ("AXA") brings back AXA BetterMe Weekend on 8 to 9 October 2022 at...
Fosun Pharma and MAIA Pharmaceuticals Jointly Announce the Successful Commercialization of Only FDA Approved 20ml Sodium Phenylacetate and Sodium Benzoate (SPSB) Liquid Product
PRINCETON, N.J., Sept. 26, 2022 /PRNewswire/ -- Shanghai Fosun Pharma (Group) Co., Ltd. ("Fosun Pharma", stock code: 600196.SH; 02196.HK) today announced that the 20 ml, Sodium Phenylacetate and Sodium Benzoate (SPSB) liquid product, which is under an exclusive partnership between Fosun Pharma USA Inc. ("Fosun Pharma USA"), the US-based subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma";...
Bioheng Biotech Announces Publication of Impressive Results with CD7-targeted allogeneic CAR-T cell therapy for Relapsed or Refractory T Cell Malignancies
NANJING and HANGZHOU, China, Sept. 26, 2022 /PRNewswire/ -- Nanjing Bioheng Biotech Co., Ltd, a clinical-stage biotechnology company focused on developing novel cellular immunotherapy, today announced that a phase I clinical study results of RD13-01, an anti-CD7 universal CAR-T therapy product, have been published in the reputable academic journal, Cell Research. (https://www.nature.com/articles/s41422-022-00721-y). The results published with the title of "CD7-targeted...
In commemoration of World Pharmacists Day 2022, P&G Health lauds pharmacists and the role they play in providing whole-of-body healthcare to patients
P&G Health commemorated World Pharmacists Day 2022 across the Asia Pacific, Middle East, and Africa region through a host of activities This includes the first ever P&G Health Middle-East Whole-Body Health Symposium over 2 days in which 12,813 participants from 111 countries took part SINGAPORE, Sept. 26, 2022 /PRNewswire/ -- P&G Health (NYSE:PG) commemorated World Pharmacists Day 2022...
WuXi STA Opens First High Potency Oral Drug Product Manufacturing Facility
New facility expands integrated drug product R&D and manufacturing services to global customers SHANGHAI, Sept. 26, 2022 /PRNewswire/ -- WuXi STA, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of its first high potency (HP) oral drug product manufacturing facility at its Wuxi city campus. This new facility marks a milestone for WuXi...
PharmAbcine to Participate in BIO-Europe 2022
DAEJEON, South Korea, Sept. 26, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will participate in the upcoming BIO-Europe 2022 which will take place in Leipzig, Germany on October 24 – 26, 2022. BIO-Europe is Europe's largest...
Brii Biosciences Announces Top-line Results from Phase 1 Study of BRII-296, A Long-Acting Therapy in Development for Postpartum Depression
Data demonstrated that a single administration of BRII-296 at 600 mg delivered a favorable pharmacokinetic profile and is safe and well-tolerated in healthy subjects Findings suggest BRII-296 has potential to provide a safe and effective, one-time injectable treatment option to people with PPD in an outpatient setting Company has identified an...
Alterity Therapeutics Announces Presentation of Wearable Sensor Data from the bioMUSE Natural History Study at the International Congress of Parkinson’s Disease and Movement Disorders
- Wearable sensors strongly correlated with clinical scales on motor impairment - - bioMUSE Study Validates Use of Wearable Sensors for Alterity's Ongoing Phase 2 Clinical Trial - MELBOURNE, Australia and SAN FRANCISCO, Sept. 26, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company...
